Silence Therapeutics (NASDAQ:SLN) Earns “Sell (D-)” Rating from Weiss Ratings

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “sell (d-)” rating reaffirmed by stock analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other analysts have also weighed in on the company. Wall Street Zen lowered Silence Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Tuesday, September 16th. Finally, Chardan Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Silence Therapeutics in a research report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $32.60.

Silence Therapeutics Stock Performance

Shares of NASDAQ:SLN opened at $5.25 on Wednesday. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $20.48. The business has a fifty day moving average of $5.24 and a 200-day moving average of $4.84.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.27). Silence Therapeutics had a negative net margin of 294.20% and a negative return on equity of 67.48%. The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $8.50 million. As a group, research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Massar Capital Management LP bought a new position in Silence Therapeutics during the second quarter worth about $115,000. Boothbay Fund Management LLC boosted its holdings in Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after buying an additional 2,409 shares during the last quarter. Beacon Pointe Advisors LLC bought a new position in Silence Therapeutics during the second quarter worth about $67,000. Evelyn Partners Investment Management Services Ltd boosted its holdings in Silence Therapeutics by 481.3% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock worth $77,000 after buying an additional 11,868 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Silence Therapeutics by 134.1% during the second quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock worth $48,000 after buying an additional 4,773 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.